Condition
Antiplatelet Drug-related Gastrointestinal Injury
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Not Yet Recruiting1
Unknown1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07125651Not Yet Recruiting
Gastrointestinal Bleeding is Blood Loss in the Digestive Tract, Classified as Upper or Lower. Ischemic Heart Disease is Due to Blocked Heart Arteries. Antiplatelet Drugs Help Prevent Heart Attacks But Increase GI Bleeding Risk, Especially When Used Together as Dual Therapy.
NCT03725800UnknownPrimary
Long-term MOno-Antiplatelet Drug Strategy After PerCutanEous CoronAry InterveNtion
Showing all 2 trials